RecruitingPhase 1NCT06589609
Phase 1 Clinical Trial of FluBHPVE6E7 Immunotherapy for HPV16-Associated Oropharyngeal Cancer
Studying Squamous cell carcinoma of the oropharynx
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- BlueSky Immunotherapies GmbH
- Intervention
- FluBHPVE6E7(biological)
- Enrollment
- 12 target
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2024 – 2029
Study locations (1)
- Medical University Vienna, Vienna, Austria
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06589609 on ClinicalTrials.govOther trials for Squamous cell carcinoma of the oropharynx
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT06915038ctHPVDNA in HPV Positive Squamous Cell Carcinoma of the OropharynxIndiana University
- RECRUITINGPHASE1NCT06747390Intratumoral Lidocaine Injection Before Oropharyngeal Cancer SurgeryRyan Carey
- RECRUITINGPHASE2NCT06702033The Minimalist Trial-2Washington University School of Medicine
- RECRUITINGPHASE2NCT06223568Phase II Trial of Neoadjuvant Chemotherapy (NAC) Alone or in Combination With Immunotherapy Vaccine PRGN-2009 in Subjects With Newly Diagnosed HPV-Associated Oropharyngeal (Head and Neck) CancerNational Cancer Institute (NCI)
- RECRUITINGPHASE2NCT05582122SURVEILLE-HPV: Evaluation of HPV16 Circulating DNA as Biomarker to Detect the Recurrence, in Order to Improve Post Therapeutic Surveillance of HPV16-driven Oropharyngeal CancersUNICANCER
- ACTIVE NOT RECRUITINGNCT06592716Can Recurrence of Cancer in the Oropharynx be Detected by Blood Samples?Rigshospitalet, Denmark
- RECRUITINGPHASE2NCT06323460Adaptive De-intensified Radiotherapy Using Circulating Tumor DNA in HPV- Associated Oropharyngeal CancerOhio State University Comprehensive Cancer Center
- RECRUITINGPHASE2NCT06088381Selective Adjuvant Therapy for HPV-mediated Oropharynx SCCs Based on Residual Circulating Tumor DNA Levels (SAVAL)University of Maryland, Baltimore
See all trials for Squamous cell carcinoma of the oropharynx →